The science
Traditional knowledge, modern evidence.
The active compounds interrupt sperm's ability to penetrate the egg. Sperm count, hormones, and libido are left unchanged, and the effect reverses when use stops. Our work will replicate and extend prior research to a standard the wider medical community can rely on.
Sovereign's founder has completed two exploratory proteomics studies on seminal-fluid biomarkers across structured dosing protocols. Both were designed to test a single question: does the effect documented in Indonesia reproduce under careful, modern measurement?
Study 1 — an LC-MS/MS proteomics analysis across a six-day dosing protocol — identified two proteins present at baseline and absent in the final sample: Pro-cathepsin H (an acrosomal enzyme involved in sperm–egg penetration, ~37,394 Da) and protein phosphatase 1 regulatory subunit 7 (~41,564 Da). Their molecular weights match the bands reported absent in the Indonesian Phase 2 data. These results are preliminary and require confirmation.
Study 2, a longitudinal design with escalating doses, repeated sampling, and a washout period, is complete; analysis is underway. It is built to confirm or refute the Indonesian findings and to establish the basis for a first protocol for men.
Detailed methodology and study data available under NDA.
Documented efficacy
A strong signal that needs better evidence.
Studies at the Universitas Airlangga documented efficacy of 99.46% in a Phase 2 clinical trial, with fertility returning within weeks of discontinuation. That programme reached advanced clinical stages but — critically — never published complete Phase 2 results. Sovereign treats those figures as a promising starting point to be independently confirmed.